We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,022.00
Bid: 12,624.00
Ask: 11,284.00
Change: 34.00 (0.28%)
Spread: -1,340.00 (-10.615%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Stabilisation Notice

19 Nov 2014 09:41

RNS Number : 4348X
Citigroup Global Markets Limited
19 November 2014
 



19th November 2014

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

AstraZeneca PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

Issuer:

AstraZeneca PLC

Guarantor (if any):

Aggregate nominal amount:

€ TBC

Description:

Senior Unsecured REGS Only

Offer price:

TBC

Other offer terms

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

19th November 2014

Stabilisation period expected to end no later than:

20th December 2014 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STABLBLTMBIBMMI
Date   Source Headline
23rd Sep 20217:00 amRNSNew Sustainability Committee of the Board
21st Sep 20217:00 amRNSAstraZeneca $360m Irish manufacturing investment
20th Sep 20217:00 amRNSEnhertu reduced risk of disease progression by 72%
9th Sep 20214:00 pmRNSImfinzi improves survival in NSCLC in POSEIDON
9th Sep 20217:00 amRNSPT027 PhIII asthma trials met primary endpoints
3rd Sep 20217:00 amRNSUltomiris approved in EU for children with PNH
1st Sep 20213:00 pmRNSTotal Voting Rights
26th Aug 20217:05 amRNSForxiga approved in Japan for CKD
26th Aug 20217:00 amRNSALXN1840 Wilson Phase III met primary endpoint
20th Aug 20217:05 amRNSUpdate on Ultomiris Phase III ALS trial
20th Aug 20217:00 amRNSAZD7442 prophylaxis trial met primary endpoint
16th Aug 20213:00 pmRNSDirector/PDMR Shareholding
11th Aug 20212:35 pmRNSUpdate on US review of roxadustat
9th Aug 20217:05 amRNSForxiga approved in the EU for CKD
9th Aug 20217:00 amRNSEnhertu head-to-head trial meets primary endpoint
2nd Aug 20213:00 pmRNSTotal Voting Rights
2nd Aug 20217:00 amRNSSaphnelo approved in the US for SLE
29th Jul 20217:00 amRNSAZN: H1 2021 Results
26th Jul 20217:00 amRNSUltomiris recommended in EU for children with PNH
22nd Jul 20217:00 amRNSDirectorate Change
21st Jul 20213:56 pmRNSDirector/PDMR Shareholding
21st Jul 20213:45 pmRNSTotal Voting Rights
21st Jul 20211:45 pmRNSAcquisition of Alexion completed
19th Jul 20217:00 amRNSImfinzi approved in China for extensive-stage SCLC
16th Jul 20217:00 amRNSStatus on US FDA Advisory Committee for roxadustat
15th Jul 20215:30 pmRNSAstraZeneca
14th Jul 20217:08 amRNSAstraZeneca-Alexion transaction cleared in the UK
8th Jul 20217:00 amRNSTezepelumab granted FDA Priority Review for asthma
6th Jul 20217:00 amRNSAstraZeneca-Alexion transaction cleared in the EU
1st Jul 20213:00 pmRNSTotal Voting Rights
28th Jun 20217:05 amRNSForxiga recommended in EU for patients with CKD
28th Jun 20217:00 amRNSNirsevimab PhII/III trial confirms safety profile
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
4th Jun 20217:05 amRNSLynparza reduced recurrence risk in breast cancer
4th Jun 20217:00 amRNSAstraZeneca appoints new Chief Financial Officer
2nd Jun 20217:00 amRNSPublication of Final Terms
1st Jun 20213:01 pmRNSBlock listing Interim Review
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.